From the Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, New York.
Funded in part by Affinity Health Plan Making a World of Difference Grant Program. Additional funding was provided by the William and Flora Hewlett Foundation.
The authors thank Planned Parenthood of New York City for providing the clinical site (Planned Parenthood Boro Hall) and ConnectUS and MIR3 for sending the text messages.
Preliminary results were presented at Reproductive Health 2010, September 22–25, 2010, Atlanta, Georgia. Additional results were presented at The North American Forum on Family Planning, October 22–24, 2011, Washington, DC.
The opinions expressed in this article do not necessarily reflect those of Planned Parenthood Federation of America, Inc.
Corresponding author: Paula M. Castaño, MD, MPH, Department of Obstetrics and Gynecology, Columbia University Medical Center, 622 W 168th Street, PH 16, New York, NY 10032; e-mail: [email protected].
Financial Disclosure Dr. Castaño serves on the scientific advisory board for Bayer. Dr. Westhoff is an advisory board member for Teva and Agile and is a consultant for Merck, Bayer, and Med360. The other authors did not report any potential conflicts of interest.
